drugset
drugset / Trial / NCT03333538

A Double-blind Randomized Placebo-controlled Study of Safety and Immunogenicity of GamEvac-Lyo

NCT03333538 ↗

Phase 1/2 Completed 220 enrolled Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Research Institute of Influenza, Sankt-Peterburg, Russian Federation · collab
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to evaluate immunogenicity and safety of medicinal product GamEvac-Lyo- Vector-Based Vaccine against Ebola Virus Disease

Timeline

Start
2017-11-03
Primary completion
2018-11-30
Completion
2018-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject GamEvac-Lyo Unknown — Intramuscular
Subject GamEvac-Lyo (component A) Unknown — Intramuscular
Subject GamEvac-Lyo (component B) Unknown — Intramuscular

Indications

No indication recorded.